These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15098089)

  • 21. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder.
    Yoshida M; Masunaga K; Nagata T; Yono M; Homma Y
    J Pharmacol Sci; 2010; 112(2):128-34. PubMed ID: 20134115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local effects of antimuscarinics.
    Masuda H; Kim YT; Tyagi S; Chancellor MB; de Miguel F; Yoshimura N
    Urol Clin North Am; 2006 Nov; 33(4):511-8, ix-x. PubMed ID: 17011387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solifenacin in the management of the overactive bladder syndrome.
    Robinson D; Cardozo L
    Int J Clin Pract; 2005 Oct; 59(10):1229-36. PubMed ID: 16178992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimuscarinics and overactive bladder: other mechanism of action.
    Yamaguchi O
    Neurourol Urodyn; 2010; 29(1):112-5. PubMed ID: 19693952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary Excretion Contributes to Long-Lasting Blockade of Bladder Muscarinic Receptors by Imidafenacin: Effect of Bilateral Ureteral Ligation.
    Ito Y; Kuraoka S; Endo S; Takahashi A; Onoue S; Yamada S
    J Pharmacol Exp Ther; 2017 Jan; 360(1):69-74. PubMed ID: 27831487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential Future Pharmacological Treatment of Bladder Dysfunction.
    Andersson KE
    Basic Clin Pharmacol Toxicol; 2016 Oct; 119 Suppl 3():75-85. PubMed ID: 26990140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging.
    Yoshida M; Miyamae K; Iwashita H; Otani M; Inadome A
    Urology; 2004 Mar; 63(3 Suppl 1):17-23. PubMed ID: 15013648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Muscarinic acetylcholine receptors in the urinary tract.
    Andersson KE
    Handb Exp Pharmacol; 2011; (202):319-44. PubMed ID: 21290234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New perspectives on the overactive bladder: pharmacokinetics and bioavailability.
    Gupta S; Sathyan G; Mori T
    Urology; 2002 Nov; 60(5 Suppl 1):78-80; discussion 80-1. PubMed ID: 12493362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.
    Maruyama S; Oki T; Otsuka A; Shinbo H; Ozono S; Kageyama S; Mikami Y; Araki I; Takeda M; Masuyama K; Yamada S
    J Urol; 2006 Jan; 175(1):365-9. PubMed ID: 16406943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic administration of anticholinergics in rats induces a shift from muscarinic to purinergic transmission in the bladder wall.
    Uvin P; Boudes M; Menigoz A; Franken J; Pinto S; Gevaert T; Verplaetse R; Tytgat J; Vennekens R; Voets T; De Ridder D
    Eur Urol; 2013 Sep; 64(3):502-10. PubMed ID: 23711542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New pharmacological treatment concepts for overactive bladder].
    Michel MC
    Urologe A; 2003 Jun; 42(6):807-11. PubMed ID: 12851772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacotherapy of overactive bladder.
    Athanasopoulos A
    Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emptying against outflow obstruction--pharmacological aspects.
    Andersson KE
    Scand J Urol Nephrol Suppl; 1997; 184():77-84. PubMed ID: 9165626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors.
    Frazier EP; Peters SL; Braverman AS; Ruggieri MR; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):449-62. PubMed ID: 18060543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly.
    Kay GG; Granville LJ
    Clin Ther; 2005 Jan; 27(1):127-38; quiz 139-40. PubMed ID: 15763613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of muscarinic receptor antagonists in urgency and nocturia.
    Michel MC; de la Rosette JJ
    BJU Int; 2005 Sep; 96 Suppl 1():37-42. PubMed ID: 16083453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.